Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the level of availability of Ozempic to NHS patients.

The Department has worked intensively with industry, NHS England, the Medicines and Healthcare products Regulatory Agency, and others in the supply chain to resolve the ongoing supply issues with glucagon-like peptide-1 receptor agonists, including Ozempic. We continue to monitor the situation, ensuring medicines remain available for new patients with type 2 diabetes, as well as those unable to obtain their existing treatment. Any patient who is worried about their condition, or access to these medications, should speak to their clinician in the first instance.